相关实验视频
Updated: Jan 16, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
马兹杜蒂德:首次获得批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
马兹杜提德是一种双GcgR和GLP-1R激动剂,已在中国批准用于肥胖或超重的成年人长期体重管理和2型糖尿病. 这标志着该药物的重要里程碑.
科学领域:
- 药理学和内分泌学 药理学和内分泌学
- 代谢疾病 代谢疾病
- 药物开发 药物开发
背景情况:
- 马兹杜提德是一种新型的双重激动剂,向葡萄糖受体 (GcgR) 和类似葡萄糖-1受体 (GLP-1R).
- 它是为体重管理和2型糖尿病 (T2D) 治疗而开发的.
- 伊利利利利和公司和Innovent Biologics正在合作开发它.
研究的目的:
- 要总结mazdutide.tide的发展里程碑.
- 为了突出其首次批准的长期体重管理在肥胖或超重的成年人.
- 详细说明其在T2D中对血糖控制的后续批准.
主要方法:
- 对临床发展和监管里程碑的审查.
- 对药物的双重作用机制 (GcgR和GLP-1R激素) 的分析.
- 已批准的指示和正在进行的临床评估的摘要.
主要成果:
- 马兹杜提德于2025年6月在中国首次获得批准,用于长期体重控制.
- 批准标准包括特定的BMI值或BMI与并发症.
- 2025年9月在中国的第二次批准是针对T2D成年人的血糖控制.
结论:
- 马兹杜泰德的双重GcgR/GLP-1R激进作用为肥胖和T2D提供了一个有前途的治疗选择.
- 该药物的发展里程碑包括中国对不同适用症的连续批准.
- 对于其他代谢和相关疾病,正在进行进一步的临床评估.
更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
08:38Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
相关概念视频
FDA Approved Drugs: Changes to Approved Drugs
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Dipeptidyl Peptidase 4 Inhibitors
Drug Regulation
Bioequivalence studies: Biowaivers